Core Viewpoint - Kingsray Biotechnology (01548) announced that CARVYKTI® is expected to generate approximately $555 million in net trade sales for the quarter ending December 31, 2025, based on the collaboration and licensing agreement established with Janssen Biotech, Inc. on December 21, 2017 [1] Group 1 - Kingsray Biotechnology has a collaboration and licensing agreement with Janssen Biotech, Inc. [1] - The projected net trade sales for CARVYKTI® are significant, amounting to approximately $555 million [1]

荃信生物-B(02509)发布公告，于2026年1月21日该公司斥资98.88万港元回购4.4万股，回购价格为每股 22.08-22.50港元。 ...

Group 1 - The company successfully completed the recruitment of 104 patients for the Phase III clinical trial of IMM01 (Tadapaximab) for first-line treatment of chronic myelomonocytic leukemia (CMML) by December 31, 2025, and expects to complete the recruitment of 132 patients needed for interim analysis by the end of March 2026 [1] - The board confirmed that the company's business operations and clinical development remain normal, with no significant adverse changes in the business operations and financial status [1] Group 2 - IMM01 (Tadapaximab) is an innovative targeted CD47 molecule and the first SIRPα-Fc fusion protein to enter clinical stages in China, designed to activate macrophages through a dual mechanism [2] - The product has received orphan drug designation from the U.S. Food and Drug Administration for first-line treatment of CMML in combination with Azacitidine in November 2023 [2] - The company holds global intellectual property and commercialization rights for IMM01 (Tadapaximab), with a patent family that includes granted patents in China, the United States, Japan, and the European Union [2]

2025年度，公司预计归属于母公司所有者的净利润较去年同期实现大幅增长，主要受益于国内外收入增 长、股权转让收益。(1)在国内市场，公司在集采获得的市场覆盖优势上，不断深耕和拓宽市场，胰岛 素制剂产品的销量与销售额同步实现大幅增长。(2)在国际市场，公司积极推进国际化战略，在"一带一 路"沿线及新兴市场拓展成效显著，成功赢得了更多国际客户的信任和合作机会，在多个关键市场取得 了销售增长。(3)2025年度，公司与广东横琴甘瓴企业管理有限责任公司(以下简称"横琴甘瓴")达成一致 协议，公司将全资子公司甘甘医疗科技江苏有限公司(以下简称"甘甘江苏")合计70%的股权分两步转让 予横琴甘瓴。2025年度，公司已完成首步交易，成功转让甘甘江苏55%的股权，投资收益增加，使公司 净利润增加。 智通财经APP讯，甘李药业(603087.SH)发布2025年年度业绩预增公告，预计2025年年度实现归属于母 公司所有者的净利润为11.00亿元到12.00亿元，与上年同期(法定披露数据)相比，将增加4.85亿元到5.85 亿元，同比增加78.96%到95.23%。 ...

2025年度，公司预计归属于母公司所有者的净利润较去年同期实现大幅增长，主要受益于国内外收入增 长、股权转让收益。(1)在国内市场，公司在集采获得的市场覆盖优势上，不断深耕和拓宽市场，胰岛 素制剂产品的销量与销售额同步实现大幅增长。(2)在国际市场，公司积极推进国际化战略，在"一带一 路"沿线及新兴市场拓展成效显著，成功赢得了更多国际客户的信任和合作机会，在多个关键市场取得 了销售增长。(3)2025年度，公司与广东横琴甘瓴企业管理有限责任公司(以下简称"横琴甘瓴")达成一致 协议，公司将全资子公司甘甘医疗科技江苏有限公司(以下简称"甘甘江苏")合计70%的股权分两步转让 予横琴甘瓴。2025年度，公司已完成首步交易，成功转让甘甘江苏55%的股权，投资收益增加，使公司 净利润增加。 甘李药业（603087）(603087.SH)发布2025年年度业绩预增公告，预计2025年年度实现归属于母公司所 有者的净利润为11.00亿元到12.00亿元，与上年同期(法定披露数据)相比，将增加4.85亿元到5.85亿元， 同比增加78.96%到95.23%。 ...

文/飞云 单位：万元 | | 北交所 | | | | | | --- | --- | --- | --- | --- | --- | | 公司简称 | 主营业务 | 2024年营收 | 2024年净利润 | 审核结果 | 保荐/律所/审计 | | 百瑞吉 | 生物医用材料 | 23,122.72 | 5,369.42 | 通过 | 中金公司/锦天城/容诚 | 注：净利润为扣非归母净利润 常州百瑞吉生物医药股份有限公司 是一家主要从事生物医用材料等产品研发、生产和销售的高新技术企业，同时少量从事含透明 质酸功能性衍生物的功效护肤品的生产及销售业务。公司控股股东及实际控制人为舒晓正，其合计控制公司 32.36% 的股份对应的 表决权。报告期内，公司营业收入分别为 15,073.99 万元、19,817.83 万元、23,122.72 万元和 14,146.25 万元，扣非归母净利润分别 为 2,731.51 万元、4,511.50 万元、5,369.42 万元和 4,129.24 万元。 一、基本信息 公司是一家主要从事生物医用材料等产品研发、生产和销售的高新技术企业，致力于通过自主创新打造技术领先的生物模拟组织 ...

来源：市场资讯 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 有投资者在互动平台向之江生物提问："董秘您好，请问贵公司有布局创新药和AI医疗方向吗？" 针对上述提问，之江生物回应称："尊敬的投资者，您好。公司围绕'预防、诊断、治疗'一体化战略， 持续以创新驱动发展。公司在创新药与AI医疗领域均有布局，依托智能制造、数字孪生等技术持续提 升感染性疾病、优生优育、肿瘤及遗传病诊断等多个领域的解决方案。感谢您的关注！" ...

Group 1 - The company completed the recruitment of 104 patients for the Phase III clinical trial of IMM01 (Tadapaximab) for first-line treatment of Chronic Myelomonocytic Leukemia (CMML) by December 31, 2025, and expects to complete the recruitment of 132 patients for interim analysis by the end of March 2026 [1] - The board confirmed that the company's business operations and clinical development are normal, with no significant adverse changes in the business operations and financial status [1] Group 2 - IMM01 (Tadapaximab) is an innovative targeted CD47 molecule and the first SIRPα-Fc fusion protein to enter clinical stages in China [2] - The product activates macrophages through a dual mechanism by blocking the "don't eat me" signal and delivering the "eat me" signal, demonstrating good safety and macrophage activation capabilities [2] - IMM01 (Tadapaximab) received orphan drug designation from the U.S. Food and Drug Administration for first-line treatment of CMML in November 2023 [2] - The company holds global intellectual property and commercialization rights for IMM01 (Tadapaximab), with a patent family that includes granted patents in China, the United States, Japan, and the European Union [2]

Group 1 - The core viewpoint is that the dental implant market in China has significant growth potential due to reduced medical costs from price limits on implant services and collective procurement initiatives, which have stimulated demand for dental implants [1] - The penetration rate of dental implants in China remains low compared to developed countries like the US and South Korea, indicating substantial room for growth in this sector [1] - The company is optimistic about the long-term development potential of the dental implant industry and plans to continue focusing on this advantageous area while promoting new products to expand market space [1] Group 2 - In the area of meninges products, the company benefits from the comprehensive implementation of collective procurement policies and a high domestic production rate, leading to a mature and stable industry development [1] - The company has actively participated in collective procurement projects and has consistently won bids, which has helped to solidify and enhance its market share in the meninges product segment [1] - The meninges product line is expected to become a key revenue driver for the company, providing a stable income base due to the stability of the industry and the market position of its products [1]

Core Viewpoint - Zhenghai Biological has initiated the registration phase for its intrauterine repair membrane product, having received the registration acceptance notice, with further evaluation and approval steps to follow [1] Group 1 - The intrauterine repair membrane product was officially pushed into the registration phase in early January 2023 [1] - The company has completed the clinical trial summary for its breast patch project by November 2025 and is currently preparing for product registration [1] - The company will fulfill its information disclosure obligations in accordance with regulatory requirements regarding the progress of product development [1]